D. Inglis

The vascular disrupting agent BNC105 potentiates the efficacy of VEGF and mTOR inhibitors in renal and breast cancer

G. Kremmidiotis, D. Inglis, T. Lavranos, 2014, Cancer biology & therapy.

Abstract 3910: Characterization of BNC101 a human specific monoclonal antibody targeting the GPCR LGR5: First-in-human evidence of target engagement

Nicole L. Wittwer, M. Scherer, J. Licari, 2018, Experimental and Molecular Therapeutics.

The vascular disrupting agent BNC105 potentiates the efficacy of VEGF and mTOR inhibitors in renal and breast cancer

G. Kremmidiotis, D. Inglis, T. Lavranos, 2014, Cancer biology & therapy.